Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema

The study demonstrated that chrysin enhanced the therapeutic efficacy of docetaxel (DTX) in treating non-small cell lung cancer (NSCLC) and mitigated DTX-induced edema. In vitro and in vivo experiments showed that chrysin increased DTX-induced cytotoxicity, suppressed cell proliferation, and induced apoptosis in A549 cells, while also reducing tumor growth and weight in an A549-derived xenograft model. Additionally, chrysin's anti-inflammatory properties helped prevent DTX-induced edema. These findings suggested that chrysin could be a beneficial adjuvant in DTX chemotherapy for NSCLC, warranting further preclinical and clinical studies.